Rinvoq (upadacitinib) is a prescription drug used to treat certain autoimmune conditions. This drug can interact with some medications, vaccines, and supplements. For example, Rinvoq can interact ...

Rinvoq (upadacitinib) is not safe to take while pregnant or breastfeeding. Certain factors, such as the form of Rinvoq you’re prescribed, may determine whether you should take the drug during ...

Patients in the EU with giant cell arteritis (GCA), an inflammation of the arteries, could soon have the first oral targeted treatment for the disease after AbbVie's Rinvoq was recommended for ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

continues to face erosion due to biosimilar competition. However, the decline has been less severe than initially anticipated, with analysts noting that Skyrizi and Rinvoq may be absorbing some of ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion. The company now projects more than ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel ...